Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease

Stopped early · Phase 2

Conditions studied: Hyperuricemia, Chronic Kidney Diseases

In brief

Aim 1. To determine the effect of Allopurinol treatment on renal function (glomerular filtration rate, GFR) in pediatric chronic kidney disease (CKD) patients with high uric acid levels (hyperuricemia). Aim 2. Establish whether Allopurinol treatment reduces Nlrp3 inflammasome and renal injury biomarkers.

Key facts

Study ID

NCT03865407

Run by

Virginia Commonwealth University

People needed

17

Starts

2019-03-10

Expected to finish

2020-10-07

Last updated by the study team

2021-05-27

Who can join

Age: 2 and older, up to 20. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Chronic Kidney Disease stage 1-5
• Hyperuricemic (UA >= 5.5 mg/dL)

You may not qualify if…

• Contraindication to Allopurinol
• Elevated baseline liver function tests
• Receiving acute or chronic dialysis
• Primary metabolic disorder
• Sickle cell disease
• Autosomal Dominant Polycystic Kidney Disease
• Cystinosis
• Bartter or Gitelman Disease
• Pregnant or nursing

Where it is running

• Virginia Commonwealth University — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.